Sung Uk Lee1, Sang Min Yoon2, Jason Chia-Hsien Cheng3, Tae Hyun Kim1,4, Bo Hyun Kim4, Jin-Hong Park2, Jinhong Jung2, Chiao-Ling Tsai3, Yun Chiang3, Joong-Won Park4. 1. Center for Proton Therapy, National Cancer Center, Goyang, South Korea. 2. Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea. 3. Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. 4. Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang, South Korea.
Abstract
Background: No studies evaluating the clinical outcomes of radiotherapy (RT) for hepatocellular carcinoma (HCC) in the caudate lobe have been available to date. The purpose of this study was to evaluate the effectiveness and safety of RT for HCC in the caudate lobe. Material and Methods: Seventy patients with HCC in the caudate lobe treated with RT from a multi-institutional database were included in this study. The median equivalent dose in 2 Gy (EQD2) was 80.0 Gy10 (range, 31.3-99.3), and freedom from local progression (FFLP), progression-free survival (PFS), and overall survival (OS) rates were evaluated. Results: The median time of follow-up was 47.9 months (range, 3.4-127), and the 5-year FFLP, PFS, and OS rates were 80.6% [95% confidence interval (CI), 70.8-91.8], 13.8% (95% CI, 7.5-25.4), and 51.3% (95% CI, 39.9-66.1), respectively. In the multivariate analysis, the radiation dose was significantly associated with the FFLP rate [hazard ratio (HR), 0.57 per 10 Gy10 increase, p = 0.001], and the status of FFLP was significantly associated with OS (HR, 2.694, p = 0.014). The overall rate of ≥grade 3 adverse events was 5.7% (4 of 70), and RT-related mortality was not observed. Conclusion: RT for HCC in the caudate lobe showed promising FFLP and OS rates with safe toxicity profiles. These findings suggest that RT may be a promising treatment option for HCC in the caudate lobe.
Background: No studies evaluating the clinical outcomes of radiotherapy (RT) for hepatocellular carcinoma (HCC) in the caudate lobe have been available to date. The purpose of this study was to evaluate the effectiveness and safety of RT for HCC in the caudate lobe. Material and Methods: Seventy patients with HCC in the caudate lobe treated with RT from a multi-institutional database were included in this study. The median equivalent dose in 2 Gy (EQD2) was 80.0 Gy10 (range, 31.3-99.3), and freedom from local progression (FFLP), progression-free survival (PFS), and overall survival (OS) rates were evaluated. Results: The median time of follow-up was 47.9 months (range, 3.4-127), and the 5-year FFLP, PFS, and OS rates were 80.6% [95% confidence interval (CI), 70.8-91.8], 13.8% (95% CI, 7.5-25.4), and 51.3% (95% CI, 39.9-66.1), respectively. In the multivariate analysis, the radiation dose was significantly associated with the FFLP rate [hazard ratio (HR), 0.57 per 10 Gy10 increase, p = 0.001], and the status of FFLP was significantly associated with OS (HR, 2.694, p = 0.014). The overall rate of ≥grade 3 adverse events was 5.7% (4 of 70), and RT-related mortality was not observed. Conclusion: RT for HCC in the caudate lobe showed promising FFLP and OS rates with safe toxicity profiles. These findings suggest that RT may be a promising treatment option for HCC in the caudate lobe.
Authors: Daniel R Wahl; Matthew H Stenmark; Yebin Tao; Erqi L Pollom; Elaine M Caoili; Theodore S Lawrence; Matthew J Schipper; Mary Feng Journal: J Clin Oncol Date: 2015-11-30 Impact factor: 44.544
Authors: Theodore S Hong; Jennifer Y Wo; Beow Y Yeap; Edgar Ben-Josef; Erin I McDonnell; Lawrence S Blaszkowsky; Eunice L Kwak; Jill N Allen; Jeffrey W Clark; Lipika Goyal; Janet E Murphy; Milind M Javle; John A Wolfgang; Lorraine C Drapek; Ronald S Arellano; Harvey J Mamon; John T Mullen; Sam S Yoon; Kenneth K Tanabe; Cristina R Ferrone; David P Ryan; Thomas F DeLaney; Christopher H Crane; Andrew X Zhu Journal: J Clin Oncol Date: 2015-12-14 Impact factor: 44.544
Authors: Hyejung Cha; Hee Chul Park; Jeong Il Yu; Tae Hyun Kim; Taek-Keun Nam; Sang Min Yoon; Won Sup Yoon; Jun Won Kim; Mi Sook Kim; Hong Seok Jang; Youngmin Choi; Jin Hee Kim; Chul Seung Kay; Inkyung Jung; Jinsil Seong Journal: Cancer Res Treat Date: 2016-06-13 Impact factor: 4.679
Authors: Tae Hyun Kim; Joong-Won Park; Bo Hyun Kim; Eun Sang Oh; Sang Hee Youn; Sung Ho Moon; Sang Soo Kim; Sang Myung Woo; Young-Hwan Koh; Woo Jin Lee; Dae Yong Kim Journal: Front Oncol Date: 2020-04-28 Impact factor: 6.244